ArticleFrontiers in endocrinology2022
Divergent Associations Between Serum Androgens and Ovarian Reserve Markers Revealed in Patients With Polycystic Ovary Syndrome.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 8 citations in OpenAlex.
- Effects of yoga interventions on Anti-Müllerian hormone, androgen levels, and metabolic parameters in women with polycystic ovary syndrome: a systematic review.BMC complementary medicine and therapies · 2026Pooled it
- Anti-Müllerian hormone levels and live birth rate in polycystic ovary syndrome patients undergoing assisted reproductive technology: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- A meta-analysis: Effect of androgens on reproduction in sows.Frontiers in endocrinology · 2023Pooled it
- A Simplified and Robust LC-MS/MS Method for Simultaneous Quantification of Six Steroid Hormones Associated With Polyendocrine Metabolic Ovarian Syndrome.Biomedical chromatography : BMC · 2026Article
- Reassessing the Luteinizing Hormone/Follicle-Stimulating Hormone Ratio in Polycystic Ovary Syndrome: Associations With a Possible Neuroendocrine and Anti-Müllerian Hormone-Related Phenotype.Clinical endocrinology · 2026Observational
- Article
- Study the Changing Trends of Age at Diagnosis of Breast Carcinoma in Correlation with Polycystic Ovarian Syndrome, Obesity, and Nutritional Status.Annals of African medicine · 2026Observational
- Exploring the biological functions of PCOS: identifying hub androgen-related genes through bioinformatics.Frontiers in medicine · 2026Article
- Outcome-specific shifts in homocysteine-androgen correlations in polycystic ovary syndrome.Frontiers in endocrinology · 2026Article
- Pre-Conception Androgen Levels and Obstetric Outcomes in Polycystic Ovary Syndrome: A Single-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2024Article
- Androgen excess: a hallmark of polycystic ovary syndrome.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of excess androgen in ovarian reserve remains unclear in patients with polycystic ovary syndrome (PCOS). Our study highlights the associations of serum androgen levels and ovarian reserve markers in PCOS and non-PCOS women. Methods: Totally 584 menstrual abnormalities women of 20-45 years were retrospectively evaluated at the Beijing Obstetrics and Gynecology Hospital between January 2021 to October 2021. The enrolled patients were classified into two groups: the PCOS group (n=288) and the non-PCOS group (n=296) based on the Rotterdam consensus for PCOS diagnosis. The serum androgens, including testosterone (T), free testosterone (FT, calculated), bioavailable testosterone (Bio-T, calculated), androstenedione (A2), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS) were assessed with an in-house developed liquid chromatography tandem mass spectrometry (LC-MS/MS) method. The associations between the serum androgens and the hormone markers commonly used for evaluating ovarian reserve function, such as anti-mullerian hormone (AMH) and the ratio of luteinizing hormone (LH)/follicle stimulating hormone (FSH) were explored. Results: The serum T, FT, Bio-T, A2, DHT, DHEA, DHEAS, AMH and LH/FSH of the PCOS group were 51.7 ± 23.2 ng/dL/mL, 8.5 ± 5.0 pg/mL, 210.1 ± 127.7 pg/mL, 1.9 ± 0.8 ng/mL, 0.2 ± 0.1 ng/mL, 6.4 ± 4.2 ng/mL, 2431.0 ± 1030.7 ng/mL, 6.7 ± 3.8 ng/mL, and 1.8 ± 1.4 respectively, which were significantly higher than those in the non-PCOS group ( Conclusions: The serum androgen levels are positively associated with ovarian reserve markers in both of the PCOS and the non-PCOS patients in our study. In the PCOS group, the highest AMH level was observed in the subjects with the T elevation subgroup, suggesting that T is more closely related with the increase of AMH when compared with other androgens investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.